Introduction
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most commonly known inherited disorder in man, and is estimated to affect 400 million people worldwide.' The highest prevalence rates (with gene frequencies in the range of 5-25% are found in tropical Africa, the Middle East, tropical and sub-tropical Asia, some parts of the Mediterranean, and in Papua New Guinea. The spectacular advances in molecular biology of the last decade are helping to unravel the molecular basis of its biochemical and clinical diversity. It serves as a model for the clinician ofthe importance of the environment in determining the clinical expression of genetic disease. For the population biologist, its study has yielded important insights into the interaction of host red cells with the malaria parasite and the influence of this interaction on human genetic polymorphism. Most human pathology due to G6PD deficiency is preventable by population screening and avoidance of precipitants, thus posing a challenge for epidemiologists and community physicians. There are several excellent recent reviews. [2] [3] [4] [5] Biochemical and genetic basis G6PD is a cytoplasmic enzyme that is distributed in all cells. It catalyses the first step in the hexose monophosphate pathway, to produce NADPH, which is required for reactions of various biosynthetic pathways as well as for the stability of catalase and the preservation and regeneration of the reduced form of glutathione (GSH). Catalase and GSH are essential for the detoxification of hydrogen peroxide, and the defence of cells against this compound depends ultimately and heavily on G6PD. This is especially true in red cells, which are exquisitely sensitive to oxidative damage and in which other NADPH-producing enzymes are lacking. G6PD in its active enzyme form is made up of either two or four identical subunits, but the three-dimensional structure of the protein remains to be determined. The complete primary sequence of 515 amino acids has been determined from the cDNA sequence, which was determined in 1986. 6 The gene encoding G6PD is on the long arm of the X chromosome (band Xq28), and spans 18 kb. G6PD deficiency is genetically heterogeneous and about 400 different variant enzymes have been reported. These have been categorized according to criteria established by the World Health Organization,7'8 and are divided into five classes (Table I) according to residual enzyme activity. DNA sequence analysis of these mutants has been completed for about 65 mutants2'9 and a number of interesting features have emerged: 1. The overwhelming majority result from single point mutations resulting in amino-acid substitution. Only three deletions have hitherto been reported and the largest is only eight amino acids.'0"' This is in keeping with the notion that G6PD is a 'house-keeping' gene that is ubiquitously expressed and a small amount of G6PD activity is essential for all cells. 2. Many variants that were regarded as distinct based on their biochemical features have emerged as being identical; whereas some that were thought to be identical have been found to be different. No clear structure-function relationships have emerged thus far, though the cluster of Class 1 variants around residues 386 and lysine 205 have led to the suggestion that these are the NADP+ and G6P binding sites, respectively.2 3. Very few of the severely deficient variants are polymorphic, whereas most of the polymorphic variants are associated with mild deficiency. This is further evidence that the selective pressure for the emergence of these mutations is the relative protection afforded against Plasmodium falciparum malaria. At least five polymorphic and mildly deficient 'double' mutants share the mutation found in the non-deficient A + variant. The phenomenon of X-chromosome inactivation also offers a clue as to why female heterozygotes appear to have greater protection against malaria than do deficient male hemizygotes. In vitro culture studies have shown that the growth of malaria parasites is impaired upon first passage from normal to G6PD-deficient red cells but that through subsequent passages they can adapt and grow normally.'5 Such 'adaptation' occurs as the parasite's own G6PD gene is induced to protect it from oxidant stress.'6 The female heterozygote's red cell population is a mosaic of deficient and normal cells, and 'adaptation' does not occur in these circumstances. '7 Clinical manifestations Most G6PD-deficient individuals are entirely asymptomatic and the overwhelming majority of the remainder only develop symptoms in response to oxidant stress. The commmonest clinical manifestations are neonatal jaundice and acute haemolytic anaemia related to drugs, infection or ingestion of fava beans. The critical role of environmental precipitants has been recognized since the earliest descriptions of G6PD deficiency. Pythagoras is said to have warned his disciples against the dangers of eating fava beans (Vicia faba; broad beans). Observant practitioners had noticed that favism appeared to 'run in families'.'8 It was also clear that only some individuals were susceptible to haemolytic anaemia caused by drugs before the discovery by Carson et al. '9 in Chicago that primaquine-sensitive people had a very low level of G6PD activity in their red cells.
Mechanism ofhaemolysis
The detailed mechanism of haemolysis is not fully known but it undoubtedly results from the inability of G6PD-deficient red cells to withstand the oxidative damage produced, directly or indirectly by an exogenous trigger. The identity of the G6PD variant, and hence the residual enzyme activity, is clearly an important variable. Residual activity is below a critical level in Class 1, NADPH production is inadequate for the steady-state requirements of the red cell, and chronic non-spherocytic haemolytic anaemia (CNSHA) results. Neonatal erythrocytes have depressed levels of vitamin E, glutathione reductase and catalase,20'2' making them more susceptible to oxidant haemolysis.
Certain drugs22 and infectious agents (for example, influenza A virus23) stimulate the hexose monophosphate shunt pathway in normal red cells, indicating that in their presence increased NADPH production is required. Hydrogen peroxide is generated by activated polymorphonuclear neutrophils. 24 Based on studies of the effect of fractionated extracts on erythrocyte metabolism, the toxic components of fava beans have been suggested to be the pyrimidine aglycones, divicine and isouramil25 '26 
Drug-induced haemolytic anaemia
A critical analysis of the data whereby individual drugs have been implicated in the causation of haemolysis in G6PD-deficient subjects has been conducted by Beutler32 who uncovered a discrepancy between the relatively small list of drugs for which there is strong evidence linking them to haemolytic anaemia (Table II) and a much larger list of agents for which the evidence is less secure. The degree of haemolysis is also influenced by the activity of the host G6PD activity, the dose and duration of therapy, and the presence of additional oxidant stress, for example, infection. Furthermore, clinical and haematological assessment of haemolysis has notoriously low sensitivity, in that even a two-to three-fold increase in red cell destruction may not produce a significant anaemia or reticulocytosis. Clinical haemolysis andjaundice typically begin within 2 to 3 days of starting the drug. The haemolysis is largely intravascular and it is characteristically associated with haemoglo- The mainstay of prevention is avoidance of fava beans. Experience in Sardinia has demonstrated the value of neonatal screening and health education in reducing the incidence of favism within that community.' The mainstay of treatment remains blood transfusion in severe cases. The original observation suggesting arrest of haemolysis by desferrioxamine47 has been disputed,48 but a recent larger study appears to confirm that a single bolus of desferrioxamine may be useful as an adjunct to red cell transfusion. 49 The proposed mechanism is that desferrioxamine reduces iron-dependent formation of damaging oxidant radicals (for example, hydroxyl ions).
It has been widely held that favism is only associated with the more severely deficient amongst the polymorphic variants of G6PD (particularly G6PD Mediterranean); and specifically that G6PD
A-in not associated with favism. This is not correct, as typical attacks of favism have been well documented in subjects of African origin with the A-variant.50 Neonataljaundice G6PD deficiency is the commonest red cell enzymopathy to cause neonatal haemolysis and jaundice. The best population data are available from West Africa,5' the Mediterranean52'53 and the Far East (for example, Thailand54) and it is clear that perhaps as many as one third of all males with neonatal jaundice have G6PD deficiency, and a similar proportion of male children with G6PD deficiency develop neonatal jaundice (NNJ). Kernicterus has been described in all population groups. G6PD deficiency is a less frequent cause of NNJ among subjects of African descent in the USA, and of Greek ancestry in Australia, than in the countries of origin of these populations,' although the differences are perhaps less marked than originally thought. 
Diagnosis
This is based on the clinical history and haematological findings, including anaemia, reticulocytosis and characteristic red cell changes (for example, 'bite' cells and Heinz bodies, produced by adherance of oxidized and denatured red cell proteins, and haemoglobins to the cell membrane).
Assays of G6PD activity6'-63 depend on measuring the rate ofproduction ofNADPH from NADP in red cells, and the assay may be performed on a sequestrene (EDTA) or heparinized blood sample. Enzyme activity declines with red cell age and is highest in reticulocytes. Assay results obtained after an acute haemolytic episode should always be confirmed during the steady state, as a reticulocytosis may rarely lead to a false-negative result. Most haematology laboratories in the UK utilize screening tests, which are rapid and can reliably distinguish between affected men and heterozygous females; formal biochemical characterization involves enzyme purification from red cells, assay of activity by spectrophotometry and enzyme electrophoresis, and is only necessary in selected cases (for example, if a new variant is suspected).
Treatment
The most important aspect of management is to avoid precipitating causes ofhaemolysis (for example, drugs, fava beans). Haemolysis is usually self-limiting, but in severe cases red cell transfusion may be required. Red cells from G6PD-deficient donors are acceptable for transfusion purposes64 except in the case of exchange transfusion for neonatal jaundice, which should be performed after screening the donor unit for G6PD deficiency.65 Folic acid (5 mg daily) is required long term for all patients with chronic haemolysis and should be given for 2-3 weeks following an acute haemolytic event. Patients with CNSHA are variably anaemic in the steady state and, if they are symptomatic or require transfusion therapy, splenectomy should be considered. Long-term therapy with vitamin E and oral selenium are not of proven value.6667 All other patients with G6PD deficiency should not be anaemic during the steady state and, if they are, an alternative or additional diagnosis (for example, co-existence of G6PD deficiency with another cause of CNSHA such as pyruvate kinase deficiency68) must be considered.
Renal failure can complicate acute intravascular haemolysis (particularly due to drugs and fava beans). Neonatal jaundice arising as a result of haemolytic anaemia requires closer monitoring and earlier therapy than jaundice due to other causes, for example, breast milk jaundice. 69 
Future prospects
In spite of the enormous increase in our understanding, much remains to be learnt about G6PD deficiency. The lack of detailed knowledge of the tertiary structure of the enzyme hampers attempts to understand structure-function relationships.70 Molecular analysis of deficient variants will help but there is an important need to continue to perform full biochemical characterization of variants subjected to DNA sequence analysis. The lack of severe clinical effects in the overwhelming majority of deficient individuals means that antenatal diagnosis (which has already been performed7") and gene replacement therapy2 will remain largely of theoretical interest. Much greater practical benefit will result from the institution of community screening programmes72 so that appropriate educational material can be targeted towards affected patients and their carers.
